SCA
LGND icon

Snowden Capital Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Snowden Capital Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-83
Closed -$8K – 1618
2021
Q4 		$8K Buy
+83
New +$7.67K ﹤0.01% 1583

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Snowden Capital Advisors's LGND Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2022, closing a stake of 83 shares — an estimated $8K sold.

Snowden Capital Advisors first reported a position in LGND in Q4 2021 and held it in 1 quarter. The position peaked at $8K in Q4 2021. 208 funds tracked by Wall St. Rank hold LGND as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 83 Ligand Pharmaceuticals shares in Q1 2022, an estimated $8K.
  • Snowden Capital Advisors first reported a position in Ligand Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Ligand Pharmaceuticals position peaked at $8K in Q4 2021.
  • 208 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.